Should you buy CSL and ResMed shares in January?
Goldman has a buy rating and $325.40 price target on CSL's shares. This implies potential upside of 19% for investors over ...
Goldman Sachs tips ResMed shares to rocket 30% to a record high
The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...
Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
WebMD15d
Sleep Apnea Treatments Compared
How do you know which sleep apnea treatment is right for you? There are a number of ways to treat your symptoms and help you get a restful night’s sleep. Talk with your doctor before you try one.
Penn Live27d
The CPAP machine nightmare: A patient’s journey through America’s broken healthcare system | Opinion
For over 20 years, I have relied on a CPAP machine to manage my sleep apnea—a life-threatening condition that, if left untreated, can cause serious complications, including death during sleep.